


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound represented by the following structural formula:



(I)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

m is 0 or 1;

p₁ and p₂ are independently of each other 0 or 1;


R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or when p₁ and p₂ are both 0, R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring; or when at least one of p₁ or p₂ is not 0, R₁ or R₂ or both can also represent hydrogen or alkyl;

and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and polymorphs thereof.

2. (Original) The compound of claim 1, wherein p₁ and p₂ are both 0.

3. (Original) The compound of to claim 1, wherein p₁ and p₂ are both 1.

4. (Original) The compound of claim 1, wherein m is 0.
5. (Original) The compound of claim 1, wherein m is 1.
6. (Original) A compound represented by the following structural formula:




wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R_1 and R_2 are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl;

and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and polymorphs thereof.

7. (Original) A compound represented by the following structural formula:




wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other a hydrogen or an unsubstituted or substituted alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl;

and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and polymorphs thereof.

8. (Original) A compound represented by the following structural formula:




wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring;

and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and polymorphs thereof.

9. (Original) A compound represented by the following structural formula:



wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R₁ and R₂ are independently of each other an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl or alkylheterocyclyl; or R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached can also represent a nitrogen-containing heterocyclic ring;

and pharmaceutically acceptable salts, solvates, hydrates, prodrugs and polymorphs thereof.

10. (Currently amended) The compound of ~~any of claims 1 to 9~~, wherein n is 5.

11. (Currently amended) The compound of ~~any of claims 1 to 9~~, wherein n is 6.

12. (Currently amended) The compound of ~~any of claims 1 to 11~~, wherein at least one of R₁ and R₂ is an unsubstituted or substituted phenyl, benzyl, alkylphenyl, naphthyl, biphenyl, -CH(Ph)₂, -CH=CHPh, cyclohexyl, alkylcyclohexyl, quinoliny, alkylquinoliny, isoquinoliny, alkylisoquinoliny, tetrahydroquinoliny, alkyltetrahydroquinoliny, tetrahydroisoquinoliny, alkyltetrahydroisoquinoliny, indazolyl, alkylindazolyl, benzothiazolyl, alkylbenzothiazolyl, indolyl, alkylindolyl, piperazinyl, alkylpiperazinyl, morpholiny, alkylmorpholiny, piperidinyl, alkylpiperidinyl, pyridyl or alkylpyridyl.

13. (Currently amended) The compound of claim 6 or ~~claim 7~~, wherein at least one of R₁ and R₂ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl sec-butyl or tert-butyl.

14. (Original) The compound of claim 8 or 9, wherein R₁ and R₂ together with the -CH₂-N-CH₂- group to which they are attached represent a nitrogen-containing heterocyclic ring.

15. - 20. (Cancelled).

21. (Currently amended) A composition comprising a pharmaceutically effective amount of the compound of ~~any of claims 1-14~~.

22. (Currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of ~~any of claims 1-14,~~ and a pharmaceutically acceptable carrier.

23. - 24. (Cancelled).

25. (Currently amended) A method of treating cancer in a subject in need of treatment comprising administering to said subject a therapeutically effective amount the compound of ~~any one of claims 1-14,~~ wherein said amount is effective to treat cancer in said subject.

26. (Currently amended) The method of claim 25, wherein the cancer is selected from the group consisting of acute leukemia, ~~such as~~ acute lymphocytic leukemia (ALL), ~~and~~ acute myeloid leukemia (AML),; chronic leukemia, ~~such as~~ chronic lymphocytic leukemia (CLL), ~~and~~ chronic myelogenous leukemia (CML), Hairy Cell Leukemia, cutaneous T-cell lymphoma (CTCL), noncutaneous peripheral T-cell lymphoma, lymphoma associated with human T-cell lymphotropic virus (HTLV), ~~such as~~ adult T-cell leukemia/lymphoma (ATLL), Hodgkin's disease, non-Hodgkin's lymphoma, large-cell lymphoma, diffuse large B-cell lymphoma (DLBCL),; Burkitt's lymphoma,; primary central nervous system (CNS) lymphoma,; multiple myeloma,; childhood solid tumors, ~~such as~~ brain tumor, neuroblastoma, retinoblastoma, Wilm's tumor, bone tumor, soft-tissue sarcoma, head and neck cancers, (~~e.g., oral cancer, laryngeal cancer, and esophageal cancer,~~ genito urinary cancers, (~~e.g., prostate cancer, bladder cancer, renal cancer, uterine cancer, ovarian cancer, testicular cancer, rectal cancer, and colon cancer,~~ lung cancer, breast cancer, pancreatic cancer, melanoma, ~~and other~~ skin cancers, stomach cancer, brain tumors, liver cancer, and thyroid cancer.

27. - 33. (Cancelled).

34. (Currently amended) A method of treating a patient having a tumor characterized by proliferation of neoplastic cells, comprising the step of administering to the patient a the compound of ~~any one of claims 1-14,~~ in an amount effective to selectively induce terminal

differentiation, induce cell growth arrest and/or induce apoptosis of such neoplastic cells and thereby inhibit their proliferation.

35. (Currently amended) The method of ~~any of claims 25-34~~, wherein said administering comprises administering a pharmaceutical composition comprising said compound, and a pharmaceutically acceptable carrier.

36. - 46. (Cancelled).